Avricore Health (AVCR) AI Stock Analysis

• Market Cap: $4.56M
• Dividend Yield: N/A
• Average Volume (3M): 94.98K
• Price to Earnings (P/E): 40.9
• Beta (1Y): 0.37
• Revenue Growth: 51.84%
• EPS Growth: N/A
• Country: CA
• Employees: 2
• Sector: Healthcare
• Sector Strength: 78
• Industry: Medical Diagnostics & Screening
• EPS (TTM): <0.01
• Shares Outstanding: 101,289,665
• 10 Day Avg. Volume: 80,122
• 30 Day Avg. Volume: 94,978
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.86
• Price to Cash Flow (P/CF): 4.20
• P/FCF Ratio: 5.90
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Avricore Health's strong financials and strategic corporate developments are offset by high valuation concerns and neutral technical indicators. The company's financial stability and growth potential are promising, but profitability and valuation require attention.

Avricore Health Business Overview & Revenue Model

Company Description

Avricore Health (AVCR) is a Canada-based health technology company primarily focused on developing innovative solutions in the health diagnostics sector. The company specializes in point-of-care testing technologies aimed at improving healthcare outcomes by providing accessible and timely health information. Avricore Health's core product, HealthTab, is a platform designed to deliver rapid diagnostic testing services in pharmacies and other healthcare settings, enabling patients to have immediate access to essential health data.

How the Company Makes Money

Avricore Health generates revenue through the sale and deployment of its HealthTab platform in partnership with pharmacies and healthcare providers. The company earns money by charging fees for each test conducted on its platform and through subscription models that allow pharmacies to access and utilize the HealthTab technology. Additionally, Avricore Health benefits from strategic partnerships with leading diagnostic and pharmaceutical companies, which may provide funding or revenue-sharing opportunities to further expand its market presence. The company's revenue model is heavily reliant on the adoption of its technology by healthcare networks and the volume of diagnostic tests performed.

Avricore Health Financial Statement Overview

Summary

Avricore Health demonstrates robust financial performance with strong revenue growth and operational efficiency. The balance sheet is solid with no debt, and cash flow management is improving. However, profitability remains an area for enhancement.

Income Statement

Avricore Health has shown significant improvement in its revenue, with a notable growth rate of 35.42% from the previous year. The company's gross profit margin stands at 37.94%, indicating strong cost management. However, the net profit margin is relatively low at 2.18%, which suggests room for improvement in profitability. Nevertheless, the positive trend in EBIT and EBITDA margins reflects a trajectory towards operational efficiency.

Balance Sheet

The balance sheet of Avricore Health is robust, with a strong equity ratio of 82.29%, indicating a solid financial foundation. The company has no debt, reflected in a debt-to-equity ratio of 0, which significantly reduces financial risk. Return on equity is positive at 4.14%, demonstrating effective utilization of shareholders' equity.

Cash Flow

Avricore Health's cash flow position is improving, with a strong operating cash flow to net income ratio of 8.78, indicating efficient cash management relative to earnings. The free cash flow to net income ratio is 3.41, showing a positive trend in generating free cash flow. The company has successfully shifted from negative to positive free cash flow growth.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
4.72M	3.49M	1.77M	122.81K	33.03K	33.00K
	Gross Profit
1.79M	1.20M	456.79K	30.52K	17.48K	14.50K
	EBIT
301.83K	-691.84K	-809.86K	-1.75M	-859.15K	-1.60M
	EBITDA
576.97K	-275.14K	-629.76K	-1.64M	-930.40K	-1.72M
	Net Income Common Stockholders
103.13K	-701.22K	-818.23K	-1.71M	-1.17M	-2.11M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
84.44K	286.57K	630.53K	2.01M	302.71K	13.80K
	Total Assets
1.20M	2.54M	2.57M	2.28M	440.09K	208.40K
	Total Debt
0.00	40.00K	40.00K	40.00K	1.00M	21.39K
	Net Debt
-84.44K	-236.57K	-580.53K	-1.97M	698.85K	7.59K
	Total Liabilities
314.24K	529.22K	604.89K	84.48K	1.15M	673.85K
	Stockholders Equity
885.97K	2.01M	1.96M	2.20M	-714.04K	-465.45K
Cash Flow		Free Cash Flow
351.93K	-386.46K	-1.64M	-1.37M	-1.22M	-686.41K
	Operating Cash Flow
905.87K	660.40K	-437.83K	-1.23M	-1.22M	-686.41K
	Investing Cash Flow
-553.94K	-1.05M	-1.21M	-140.36K	0.00	0.00
	Financing Cash Flow
39.10K	42.50K	253.88K	3.08M	1.51M	615.76K

Avricore Health Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.04
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:AVCR, the sentiment is Negative. The current price of 0.04 is below the 20-day moving average (MA) of 0.05, below the 50-day MA of 0.06, and below the 200-day MA of 0.15, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 42.86 is Neutral, neither overbought nor oversold. The STOCH value of 22.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:AVCR.

Avricore Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AVCR	64 Neutral	$4.56M	40.91	4.84%	―	51.84%	―
HLS	63 Neutral	C$124.63M	―	-24.49%	―	-8.60%	21.06%
GUD	59 Neutral	$598.29M	―	-3.84%	―	3.87%	-378.27%
Sector *	49 Neutral	$6.90B	0.02	-54.05%	2.46%	24.91%	-3.14%

Avricore Health Corporate Events

Avricore Health Enhances UK Healthcare with HealthTab-PKB Integration

Avricore Health Inc. has successfully integrated its HealthTab™ platform with Patients Know Best (PKB), the UK’s leading patient personal health record, enhancing data accessibility across healthcare providers and patients. This collaboration supports the UK’s shift towards community-based, preventative healthcare, allowing for seamless integration of pharmacy point-of-care testing results into personal health records, ultimately improving patient outcomes and empowering healthcare teams with comprehensive health data.

Avricore Health Reports Revenue Surge and UK Expansion

Avricore Health Inc. reported a significant rise in revenues and profitability for the third quarter of 2024, with a 58% year-over-year revenue increase. The company is strategically expanding its HealthTab™ services in the UK, capitalizing on the region’s strong investment in pharmacy-led healthcare services.

Avricore Health Shifts Focus to UK Market

Avricore Health has announced a strategic pivot to focus on the growing UK healthcare market, concluding its partnership with Canada’s Shoppers Drug Mart. This move is backed by the significant NHS investment in pharmacy services, which presents a larger opportunity for their HealthTab™ platform. The company maintains a strong cash position to support this expansion and has already initiated deployment in London.